The drug Onocase has been reviewed by the Food and Drug Administration recently. In a meeting with Onocase makers, Alfacell Corp, the FDA recommended that another clinical trial be carried out. This new trial would involve patients with malignant, unresectable mesothelioma who have already failed a course of chemotherapy treatment.
The last trial showed no significant improvement for patients with unresectable mesothelioma. However, patients who both had unresectable tumors and had failed chemotherapy treatments did show a significant improvement in survival. Another trial would serve to reinforce the data that has already been collected. However, Alfacell may need to find financing before these new trials can commence.
Once approved, this drug could be extremely helpful to certain mesothelioma patients. If you or someone you know has been diagnosed with mesothelioma, contact the mesothelioma attorneys of Williams Kherkher at 800-220-9341.